Loading...
•
Jun 30, 2021
Kiniksa Q2 2021 Earnings Report
Kiniksa reported strong Q2 2021 financial results driven by ARCALYST revenue growth.
Key Takeaways
Kiniksa Pharmaceuticals reported strong Q2 2021 results, driven by growth in ARCALYST revenue. The company is focused on advancing its pipeline and expanding ARCALYST's reach.
Total revenue was $32.3 million, a 47% increase year-over-year.
ARCALYST revenue was $31.7 million, a 49% increase year-over-year.
Net loss was $25.9 million, compared to a net loss of $24.6 million for the same period in 2020.
Cash, cash equivalents, and marketable securities were $212.1 million as of June 30, 2021.
Revenue by Segment
Forward Guidance
Kiniksa anticipates ARCALYST revenue to be between $120.0 million and $130.0 million.
Positive Outlook
- ARCALYST revenue between $120.0 million and $130.0 million
- Continued investment in ARCALYST
- Advancing mavrilimumab in GCA
- Advancing vixarelimab in prurigo nodularis
- Exploring partnering opportunities for IL-15 programs
Challenges Ahead
- Uncertainties related to COVID-19
- Potential delays in clinical trials
- Regulatory risks
- Competition from other therapies
- Dependence on ARCALYST revenue
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...